AI-CVD vs VX1+

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung AI

VX1+

by Volta Medical

AI Verdict

Tool A (AI-CVD) is designed for opportunistic screening of cardiovascular and multisystem diseases using existing CT scans, focusing on early detection and risk assessment. Tool B (VX1+) provides real-time AI-powered assistance to electrophysiologists during cardiac ablation procedures for atrial fibrillation and tachycardia. While both are cardiology AI tools, their distinct applications—diagnostic imaging analysis versus intra-procedural guidance—make them adjacent rather than direct competitors.

Choose AI-CVD if…

Choose AI-CVD if your primary objective is opportunistic screening for hidden cardiovascular and multisystem disease risks using existing CT scans. This platform is ideal for leveraging routine imaging data to enable early detection and risk stratification without requiring additional imaging, radiation, or workflow disruption.

View AI-CVD →

Choose VX1+ if…

Choose VX1+ if you require real-time, AI-powered assistance for electrophysiologists during cardiac ablation procedures for atrial fibrillation and atrial tachycardia. This software is specifically designed to identify abnormal electrograms during live interventions, enhancing the precision and efficacy of the ablation process for improved procedural outcomes.

View VX1+ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	VX1+
Pricing	Unknown	Not publicly available
Deployment	Unknown	Software application on a computing platform, integrates with existing EP recording and 3D mapping systems.
FDA Status	Unknown	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-CVD

AI-CVD leverages existing CT scans, requiring no additional imaging, radiation, contrast, or workflow disruption, making its integration into current radiology workflows seamless. This opportunistic approach minimizes active user engagement compared to VX1+'s real-time, interactive use during a cardiac ablation procedure.

Clinical Value

AI-CVD

AI-CVD offers broad opportunistic screening for multiple cardiovascular and multisystem diseases (e.g., heart disease, stroke, osteoporosis, liver steatosis) from existing CT scans, enabling early detection and impacting population health. While VX1+ significantly improves outcomes in a specific, complex interventional procedure for atrial fibrillation, AI-CVD's wider scope for early, preventive detection across a larger patient base gives it a broader clinical value.

Pricing & Value

AI-CVD

While both tools require direct contact for pricing, AI-CVD has a publicly available reimbursement code (HCPCS G0183) and rate ($88.06) for its AutoChamberu2122 module, effective April 1, 2025. This transparency and established reimbursement pathway for a key feature provide a clearer economic value proposition compared to VX1+, for which no public pricing or reimbursement details were found.

Enterprise Readiness

AI-CVD

Both tools are FDA-cleared, a crucial aspect of enterprise readiness. However, AI-CVD's cloud deployment and explicit statement of HIPAA compliance, along with its ability to process millions of existing CT scans annually, suggest superior scalability and ease of integration into large healthcare systems. VX1+ integrates with specific EP lab systems, which is good for its niche, but AI-CVD's broader applicability and cloud model offer a more robust enterprise solution.

Innovation

AI-CVD

AI-CVD's innovation lies in its paradigm-shifting approach of opportunistic, multi-system screening, transforming routine CT scans into a comprehensive prevention platform for various silent diseases. While VX1+ offers significant real-time AI guidance during complex interventional procedures, AI-CVD's ability to extract new, preventive insights from *already existing* imaging data across a broad spectrum of conditions represents a more foundational innovation in leveraging healthcare data for population health.

Support & Docs

AI-CVD

Both companies provide essential documentation like user manuals and references. However, HeartLung.AI explicitly mentions a 'Knowledge Center' and offers a free trial with a 24-hour verification and testing process, indicating a more visible and potentially proactive approach to user support and onboarding.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	VX1+
Name	AI-CVD	VX1+
Company	HeartLung Corporation	Volta Medical
Primary Purpose	FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.	AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Categories	Cardiology AI	Cardiology AI, Surgical AI
Specialties	Cardiology, Pulmonology, Radiology	Cardiology
Core Functionality / Data Input	Performs opportunistic screening from existing chest and abdominal CT scans, providing automated CT-derived anatomical and density-based measurements including Coronary Artery Calcium (CAC) scoring.	Assists in real-time identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures, compatible with existing EP recording and 3D mapping systems.